<DOC>
	<DOC>NCT00445107</DOC>
	<brief_summary>The purpose of this study is to assess the treatment effect of montelukast 10mg on the primary endpoint of Asthma Control Questionnaire(ACQ), over a 8-week period, in persistent asthma patients with or without allergic rhinitis.</brief_summary>
	<brief_title>SINGULAIR (R) as Complementary Therapy to Fixed Association Regimen (0476-363)</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Patient is currently a nonsmoker and has been a nonsmoker for at least 1 year Patient with clinical evidence of mild/moderate asthma with or without allergic rhinitis Patient has been treated in an emergency room for asthma within 4 weeks or has been hospitalized for asthma within 3 months prior to visit 1 Patient with severe asthma, upper respiratory infection, sinusitis, infectious rhinitis, nonallergic rhinitis Patient has any active, acute, or chronic pulmonary disorder that is documented by history, physical examination</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>